Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Position Increased by AlphaQuest LLC

AlphaQuest LLC lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 177.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,961 shares of the company’s stock after buying an additional 4,449 shares during the period. AlphaQuest LLC’s holdings in Denali Therapeutics were worth $142,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of DNLI. Quest Partners LLC acquired a new stake in shares of Denali Therapeutics during the third quarter worth $73,000. PNC Financial Services Group Inc. raised its position in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after purchasing an additional 885 shares during the period. Assetmark Inc. raised its position in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares during the period. KBC Group NV raised its position in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock worth $129,000 after purchasing an additional 2,731 shares during the period. Finally, E Fund Management Co. Ltd. raised its position in shares of Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after purchasing an additional 2,436 shares during the period. Institutional investors own 92.92% of the company’s stock.

Insider Transactions at Denali Therapeutics

In related news, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 12,255 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the sale, the insider now owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DNLI. William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. B. Riley reaffirmed a “buy” rating and set a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $31.00 price target on the stock. Finally, Robert W. Baird started coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target on the stock. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.20.

Denali Therapeutics Stock Performance

DNLI opened at $15.44 on Tuesday. The company has a market cap of $2.24 billion, a PE ratio of -5.59 and a beta of 1.46. The stock has a 50-day moving average of $20.17 and a 200-day moving average of $23.90. Denali Therapeutics Inc. has a 52-week low of $14.01 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.